Company

Company

Cardiac Dimensions® is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company’s initial technology platform, the Carillon® Mitral Contour System® has been designed to address functional mitral regurgitation (FMR), utilizing a novel percutaneous approach. The Carillon system has demonstrated positive results across three prospective multi-center clinical trials. Cardiac Dimensions has operations in Kirkland, Washington, Sydney, Australia and Offenbach, Germany.

Our management team is composed of seasoned industry veterans dedicated to the success of our product and our company. We are a privately owned company backed by leaders in the venture field.

Management Team

Gregory D. Casciaro

President & Chief Executive Officer

Mr. Casciaro has more than 33 years of medical device experience and has held leadership roles in both public and private companies. Prior to joining Cardiac Dimensions, he served as President and CEO of AccessClosure Inc., which was acquired by Cardinal Health in 2014. Prior to that, he was the President and CEO of XTENT Inc,, a medical device company recognized for developing a revolutionary drug-eluting stent platform. Prior to XTENT, Mr. Casciaro was the President and CEO of Orquest Inc., which was acquired by DePuy Acromed, a division of Johnson and Johnson. Prior to that, he served as President and CEO of General Surgical Innovations, which was acquired by US Surgical, a division of Tyco.

He has held several senior level positions with Devices for Vascular Intervention, a division of Guidant Corporation, and North American Instrument Corporation. In addition to his operating roles, Mr. Casciaro is on the Board of Directors for Apama Medical, Trireme Medical Inc, and Cardica. He graduated from Marquette University in Milwaukee, WI with a B.A. in Business Administration.

Rick Wypych

Chief Operating Officer & Chief Financial Officer

Mr. Wypych joined Cardiac Dimensions in 2003 and has more than 20 years of financial and strategic management experience in the financial and life sciences industries.

Prior to joining Cardiac Dimensions, Mr. Wypych served as Director of Finance and Administration at Spinal Dynamics Corporation, an early-stage artificial inter-vertebral disc company. At Spinal Dynamics, he was responsible for finance and accounting, human resources, and administration. During his tenure at Spinal Dynamics, Mr. Wypych was instrumental in developing the initial revenues of the company, the financing of operations and eventual sale of the company to Medtronic, Inc. Before joining Spinal Dynamics, Mr. Wypych served as a Senior Audit Manager for KPMG LLP managing several financial audit engagements, mergers and acquisitions projects and SEC registrations.

Mr. Wypych is also a current member of the board of directors of Simplify Medical.

Mr. Wypych holds a Bachelor of Arts degree in Business Administration from Seattle University and is a licensed Certified Public Accountant in the State of Washington.

Bob Calcote

Vice President, Operations

Mr. Calcote joined Cardiac Dimensions as Vice President of Operations in March 2014. Mr. Calcote has 33 years of manufacturing and engineering experience with over 25 years in medical device operations, product development, and quality system management. Since 2000 Mr. Calcote has held a number of senior management positions, serving as Vice President of Operations at RS Medical, Senior Vice President of Operations at ConforMIS, Vice President of Operations at Archus Orthopedics, and Vice President of Operations at Spinal Dynamics, where his management responsibilities included the manufacturing, product development, quality and regulatory activities. Earlier in Mr. Calcote’s career, he was the Director of Manufacturing at C.R. Bard’s Impra Division managing the ePTFE and polyester vascular graft manufacturing operations in the U.S. and France. Mr. Calcote received a B.S. in Electrical Engineering and an M.S. in Biomedical Engineering from the University of Texas, Arlington.

Steven Goldberg, MD, FSCAI

Chief Medical Officer

Dr. Goldberg joined Cardiac Dimensions in April 2006. In addition to serving as Chief Medical Officer for Cardiac Dimensions, Dr. Goldberg is a board certified interventional cardiologist for Rocky Mountain Heart & Lung, specializing in structural heart interventions. Previously Dr. Goldberg served as an Associate Professor of Medicine and Director of the Cardiac Catheterization Lab at University of Washington Medical Center. Dr. Goldberg works closely with Dr. Nawzer Mehta in leading the company’s clinical efforts.

Dr. Goldberg received an M.D. and B.A. from the University of Kansas and completed Fellowships in Internal Medicine and Cardiology at Cedars-Sinai Medical Center and the University of California, Irvine respectively.

Board Members

Gregory D. Casciaro

President & Chief Executive Officer

Mr. Casciaro has more than 33 years of medical device experience and has held leadership roles in both public and private companies. Prior to joining Cardiac Dimensions, he served as President and CEO of AccessClosure Inc., which was acquired by Cardinal Health in 2014. Prior to that, he was the President and CEO of XTENT Inc,, a medical device company recognized for developing a revolutionary drug-eluting stent platform. Prior to XTENT, Mr. Casciaro was the President and CEO of Orquest Inc., which was acquired by DePuy Acromed, a division of Johnson and Johnson. Prior to that, he served as President and CEO of General Surgical Innovations, which was acquired by US Surgical, a division of Tyco.

He has held several senior level positions with Devices for Vascular Intervention, a division of Guidant Corporation, and North American Instrument Corporation. In addition to his operating roles, Mr. Casciaro is on the Board of Directors for Apama Medical, Trireme Medical Inc, and Cardica. He graduated from Marquette University in Milwaukee, WI with a B.A. in Business Administration.

Mark Carnegie

M. H. Carnegie & Co.

Mark is the Founder and Managing Director of M. H. Carnegie & Co. Mark has more than 30 years of experience as an entrepreneur, investor and corporate adviser in New York, London and Sydney. He co-founded leading Australian boutique corporate advisory, venture capital and private equity firm Carnegie, Wylie & Co with John Wylie in 2000. In August 2007, Carnegie Wylie was acquired by leading Wall Street bank, Lazard Inc.

Prior to Carnegie Wylie, Mark trained on Wall Street with James D. Wolfensohn and worked with Lloyd Williams at Hudson Conway in London. Mark was the Australian and Asian representative of Hellman & Friedman for much of the 1990s. In addition to been involved in a range of diverse Australian and Asian investments, Mark has been a participant in groups that have acquired major stakes in the Courage Pub Estate, John Fairfax Holdings, Hoyts Cinemas, Formula One Holdings, SCTV, Macquarie Radio Network and Lonely Planet Publications and London Sumatra Plantations. As a corporate adviser, Mark has advised Qantas and Coles Myer on general strategic matters, Westfield on its $22 billion merger and Qantas on its JetStar Asia start-up in Singapore.

Mark holds a BA from Oxford University and a BSc (Hons) from Melbourne University. He is a former Treasurer of the Oxford Union.

Jan Garfinkle

Arboretum Ventures

Jan Garfinkle founded Arboretum Ventures in 2002 and is a Managing Director. At Arboretum, Jan focuses on promising medical technologies that enable meaningful healthcare system savings. Jan has led more than a dozen investments and currently serves as a board director of NxThera, Sonitus Medical, Cereve, and NeuMoDx. Jan’s past investments include HandyLab, where she was a board director for five years until the company was acquired by BD in 2009 for $275 million.

Prior to founding Arboretum, Jan spent 20 years in entrepreneurial healthcare companies. She held key management roles in marketing, clinical research, and sales for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI). Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation.

Jan is the past President of the Michigan Venture Capital Association, an Advisory Board member of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic, and a member of the Healthcare Advisory Board at the University of Michigan.

Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Fouad Azzam

Life Science Partners

Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich. Among others, Fouad is currently a Director at Illuminoss Medical, a company championing minimally invasive solutions for the stabilization and treatment of bone fractures. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York.

Daniel Hetu

Lumira Capital Corp.

With 20 years of investment banking, corporate and business development, and licensing experience, Daniel has been involved with life science companies at all stages of development in North America and overseas.

Before joining Lumira Capital in 2005, Daniel located in Montréal, spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire as vice president, business development North America (Shire), and vice president, corporate development (Biochem Pharma). During that period, he was involved with the in-licensing of a wide range of products and technologies as well as several financing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, Daniel served on the Company’s portfolio committee and the steering committee of strategic research collaborations.

Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian investment bank where he was involved in M&A and financing transactions across various industrial sectors.

Daniel holds an MD from Université de Sherbrooke, Québec, and an MBA from École des Hautes Études Commerciales (Montréal, Québec).

Board Observers

Gerry Brunk

Lumira Capital Corp.

Mr. Brunk is a Managing Director at Lumira Capital, a healthcare venture capital firm with offices in Toronto, Montreal and Boston. He has over 24 years of investment, consulting and entrepreneurial experience in the life sciences industry.

Before joining Lumira Capital in 2002 to establish the firm’s Boston office, Mr. Brunk was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, product licensing, R&D productivity, new product introductions, acquisitions and post-merger integration. Mr. Brunk began his career as a member of the investment banking group of Credit Suisse First Boston where his clients included public and private health care companies.

Mr. Brunk holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics.

Mr. Brunk’s current or past board roles and investment responsibilities include Archemix, BAROnova, Cardiac Dimensions, MAKO Surgical (acquired by Stryker), NephroGenex (NASDAQ: NRX), Pharmasset (acquired by Gilead Sciences), PharmAthene (AMEX: PIP), and Targanta Therapeutics (acquired by The Medicines Company). He also serves on the board of directors of Southeast BIO.

Eric H. Sillman

Aperture Venture Partners

Eric Sillman is a Managing Partner at Aperture Venture Partners, a healthcare-focused venture capital firm. He has worked at Aperture since inception and is involved in all aspects of the business. Prior to Aperture, Eric worked in a variety of professional services capacities. At UBS, he executed merger and acquisition, equity and debt transactions. At The Parthenon Group, he helped companies assess expansion strategies and e-commerce initiatives. He received his MBA from Harvard Business School and BA from Brown University.

Trevor Moody

TM strategic Advisors LLC

Trevor brings significant experience with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies. He was most recently a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with over $2.0 billion under management. Trevor co-led the medical device team for almost a decade at Frazier and became known as an active and well-regarded investor. Prior to Frazier Healthcare, he was a Senior Consultant at The Wilkerson Group.

Trevor graduated from MIT with an MS in Management (Sloan School) and the University of Southern Queensland, Australia with a Bachelor of Electrical Engineering. Trained as a Biomedical Engineer, he held product development and marketing roles at Telectronics Pacing Systems and Ventritex, both in the cardiology market.

Trevor is immediate past board chair of the Center for Infectious Disease Research, one of the largest independent, non-profit research institutes focused on diseases of the developing world. He is also a board member of electroCore, Serene Medical, and Simplify Medical.

Investors

Aperture Venture Partners is a healthcare-focused venture capital firm committed to working with exceptional entrepreneurs to build innovative companies in the medical device, biopharmaceutical, diagnostic and healthcare IT sectors. Select portfolio companies include CardioMEMS, Cameron Health, Conor Medsystems, Mako Surgical, Xlumena and Interlace Medical.

Difference Capital Financial Inc. is a publicly listed specialty finance company focused on creating shareholder value through strategic investment and advisory services in growth companies. We provide debt and equity growth capital to technology, media, and healthcare-related companies to help them create long-term shareholder value. We focus primarily on later-stage companies (post or near-commercialization) with significant intellectual property and with strong visibility to over $10m in annual revenues.

Led by a successful team with extensive experience, Difference Capital has a pool of proprietary capital and is an active investor. Our team and our investing philosophy has made Difference Capital a partner of choice for top entrepreneurs as well as venture capital and private equity firms seeking growth capital financing solutions for portfolio companies.

Built on a foundation that leverages 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.

Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.

As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.

Arboretum Ventures is a venture capital firm specializing in the healthcare sector. Founded in 2002, the firm manages $235 million in capital and has invested in more than 30 companies, five of which have exited with an aggregate valuation of approximately $1 billion. These successes have positioned Arboretum Ventures’ first two funds as top-quartile performers according to recognized industry benchmarks.

Headquartered in Ann Arbor, Arboretum invests throughout the United States, but with a preference for Midwest opportunities. The team targets capital efficient companies that can meaningfully reduce healthcare costs in our areas of expertise: devices, diagnostics, services, and IT.

LSP is one of Europe’s largest and most experienced healthcare investment firms. With a track record going back more than 25 years, we have built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society. We believe such opportunities create the most value for all parties. From our offices in Amsterdam, Munich and Boston, our team aims to back the smartest inventors with the best ideas. While their goal is to develop products and technologies that have a positive impact on society, our objective is to help inventors achieve their goals. By definition, success is often accompanied by financial returns. The combination of contributing to society and the prospect of associated financial returns is why investors entrust LSP to invest their capital.

M. H. Carnegie & Co. is one of Australia’s premier alternative asset managers based in Sydney, Australia. The fund was launched in 2011 by Mark Carnegie who has a long and successful track record in principal investing in the Australian, Asian and North American markets.

Carnegie, with over $320mn of funds under management, targets investments across venture and expansion capital, stressed/complex transactions, operating real estate and shareholder activism. The fund includes two innovation investment fund (“IIF”) allocations from the Australian Government totalling $60mn for venture related investments. In March 2013, Carnegie was awarded an IIF allocation of $40mn, the biggest ever made under this program.

Mark Carnegie, his team and the Carnegie investment committees have a significant and extensive profile and network within the Australian private investment markets resulting in an unparalleled flow of proprietary Australian-based investment opportunities and the support of a strong network of co-investors.